ISRG Q3 2024 Earnings Transcript

Intuitive Surgical reported Q3 revenue of $2.0 billion, up 17%, with DaVinci procedure growth of 18%, Ion procedures up 73% to about 25,000, and Q3 system placements rising to 379. Pro forma gross margin improved to 69.1% and pro forma EPS reached $1.84, while full-year 2024 procedure growth guidance was raised to 16%-17% and operating expense growth guidance was trimmed to 10%-12%. Offsetting the strong quarter, management flagged 2025 gross margin pressure from incremental depreciation and continued capital weakness in Europe and China.

Analysis

ISRG is still in the compounding phase where the market should care less about the headline growth rate and more about the durability of mix shift. The underappreciated lever is not just more procedures, but higher monetization per installed system via a larger base of DaVinci 5, broader leasing, and a digital layer that can raise switching costs before it meaningfully contributes to near-term revenue. That combination should keep multiple support intact even if reported gross margin temporarily flattens as depreciation and new-facility overhead ramp.

The more important second-order issue is geography. U.S. demand looks resilient, but Europe and China are becoming less about cyclical softness and more about structural capex friction: budget pressure, tender delays, and domestic competition. That means the near-term upside is increasingly concentrated in regions where ISRG can control adoption economics, while overseas growth may stay lumpy until broader launch and local regulatory milestones unlock a larger installed-base flywheel.

The clearest contrarian takeaway is that the market may be over-focusing on 2025 margin compression and underpricing the option value in platform expansion. If DaVinci 5 drives even modest improvements in utilization, procedure mix, and hospital ROI, the sales cycle could shorten in high-quality accounts while refurbished Xi inventory creates a second-wave pricing lever. The risk is that investors assume the transition is linear; if adoption stalls into next year or Asia worsens, the stock will likely de-rate on lower forward margin expectations before the new platform benefits are fully visible.

Key Decisions for Investors

• Long ISRG on 6-12 month horizon on pullbacks: the setup favors multiple support from durable procedure growth and platform mix shift; risk/reward is attractive as the market has likely already discounted much of the 2025 depreciation headwind.
• Sell downside protection on ISRG via 3-6 month cash-secured puts or put spreads after any post-earnings vol reset: monetizes elevated premium while expressing the view that margin compression is known and not a thesis-breaker.
• Pair trade: long ISRG / short a basket of hospital-capex-sensitive medtech names over 3-9 months: ISRG has more pricing power, recurring I&A exposure, and better ability to pass through budget friction than peers dependent on discretionary capital cycles.
• Avoid chasing momentum in the near term if China/Europe headlines worsen: use a staged entry, because the next leg higher likely requires clearer evidence that DaVinci 5 supply and dual-console availability are broadening rather than just deepening existing accounts.